# Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

> **NCT06176079** · — · UNKNOWN · sponsor: **Michael Ohliger, MD PhD** · enrollment: 80 (estimated)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease
- Non Alcoholic Fatty Liver
- Non Alcoholic Steatohepatitis
- NAFLD
- NASH

## Interventions

- **DRUG:** Hyperpolarized (HP) 13C
- **DRUG:** Hyperpolarized 13C-Urea
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Saline Flush

## Key facts

- **NCT ID:** NCT06176079
- **Lead sponsor:** Michael Ohliger, MD PhD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-22
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176079, "Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06176079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*